Skip to main navigation

Investors + Newsroom
Culture + Careers

Who We Are

Who We Are
Science & Innovation

Science & Innovation
Therapeutic Pipeline

Therapeutic Pipeline
Patients & Families

Patients & Families

Search
Investors + Newsroom

Investors + Newsroom
Culture + Careers

Events

Presentations

REGENXBIO Corporate Presentation – April 2024 2.2 MB

REGENXBIO New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Presentation; MDA 2024 1.3 MB

REGENXBIO Rare Disease Program Update Presentation 704.9 KB

REGENXBIO Interim Data Update from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery Presentation; Hawaiian Eye and Retina 2024 990 KB

REGENXBIO Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Presentation - AAO 2023 956.8 KB

Upcoming Events

More events are coming soon.

Past Events

Nov 08, 2023 at 4:30 PM EST

Q3 2023 REGENXBIO Inc. Earnings Conference Call

Click here for webcast

Nov 06, 2023 at 8:30 AM EST

Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery; AAO 2023

Click here for webcast

Supporting Materials

REGENXBIO Interim Data Update from Phase II ALTITUDE® Trial of ABBV-RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery Presentation - AAO 2023 956.8 KB

Pagination

First page
Previous page
Page 1
Current page 2

Contact Us

Stay connected on REGENXBIO programs and our commitment to patients.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Contact Us

Terms and Conditions

Privacy Policy

© 2024 Regenxbio Inc. • "NAV®" is a registered trademark of REGENXBIO Inc. • All Rights Reserved